Company Description
EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases.
The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.
EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jan 27, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 165 |
| CEO | Jay Duker |
Contact Details
Address: 480 Pleasant Street, Suite A-210 Watertown, Massachusetts 02472 United States | |
| Phone | 617 926 5000 |
| Website | eyepointpharma.com |
Stock Details
| Ticker Symbol | EYPT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001314102 |
| CUSIP Number | 30233G209 |
| ISIN Number | US30233G2093 |
| Employer ID | 26-2774444 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Anna Kluczewska | Chief Executive Officer of AION Diagnostics Ltd, President of AION Diagnostics Ltd and Director of AION Diagnostics Ltd |
| Dr. Jay S. Duker M.D. | President, Chief Executive Officer and Director |
| George O. Elston CPA | Executive Vice President and Chief Financial Officer |
| Dr. Ramiro Ribeiro M.D., Ph.D. | Chief Medical Officer |
| Dr. Marcia Sellos-Moura Ph.D. | Chief Scientific Officer |
| Ron I. Honig Esq. | Chief Legal Officer and Company Secretary |
| Jennifer Leonard | Chief People Officer and Senior Vice President of IT |
| David Scott Jones M.A. | Senior Vice President and Chief Commercial Officer |
| Isabelle Lefebvre | Chief Regulatory Officer |
| Michael J. Maciocio | Chief Manufacturing Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 20, 2025 | 8-K | Current Report |
| May 27, 2025 | 8-K | Current Report |
| May 9, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| May 8, 2025 | 10-Q | Quarterly Report |
| May 7, 2025 | 8-K | Current Report |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |
| Mar 6, 2025 | 10-K | Annual Report |
| Mar 5, 2025 | 8-K | Current Report |
| Mar 4, 2025 | 8-K | Current Report |